META
Meta Platforms, Inc.
META has the edge over PHI overall, supported by stronger valuation and stronger modeled upside.
PHI
PLDT Inc.
PHI has slightly lower modeled downside risk, despite its lower overall score.
META Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
META's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
PHI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Strong | |
| Under pressure |
PHI's profitability and cash flow are currently healthy, and its revenue is stable, but its balance sheet is under pressure.
META PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 19x | $624 | — |
| Cheap | 21x | $613 | -1.7% |
| Current | 21x | $624 | — |
| Fair | 27x | $803 | +29% |
| Expensive | 32x | $934 | +50% |
Historical ranges are pointers, not guarantees.
META's PE is in its cheap range at 21x. If earnings grow as analysts expect, today's price would be 19x next year's earnings.
PHI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 7.8x | $16.13 | — |
| Cheap | 8.6x | $17.63 | +9.3% |
| Fair | 11x | $22.25 | +38% |
| Expensive | 22x | $46.34 | +187% |
Historical ranges are pointers, not guarantees.
PHI has the edge over META in the historical PE scenario, which offers more potential upside but is not a forecast.
META Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Strong growth | |
| Strongly weakening | |
| Moderate | |
| Low |
META has the edge over PHI on the outlook, with more favorable earnings and revenue expectations.
PHI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Decline | |
| Stable | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect PHI's earnings and profitability to decline, with its revenue holding steady.
META Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $32.16 | +9.7% |
| Q3 2026 | $29.32 | +30% |
| Q2 2026 | $26.54 | -3.7% |
| Q1 2026 | $27.50 | +7.5% |
| Q4 2025 | $23.49 | -1.6% |
| Q3 2025 | $22.58 | +6.5% |
| Q2 2025 | $27.56 | +41% |
| Q1 2025 | $25.58 | +47% |
| Q4 2024 | $23.86 | +60% |
META has the edge over PHI on earnings, with more consistent year-over-year improvement.
PHI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $2.06 | -12% |
| Q1 2026 | $2.17 | -5.2% |
| Q4 2025 | $2.18 | -7.2% |
| Q3 2025 | $2.13 | +9.2% |
| Q2 2025 | $2.33 | +21% |
| Q1 2025 | $2.29 | +15% |
| Q4 2024 | $2.35 | +21% |
| Q3 2024 | $1.95 | +144% |
PHI earned $2.06 per share over the past year, down 12% from the year before.
META Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $64.6B | +26% |
| Q2 2026 | $60.8B | +28% |
| Q1 2026 | $56.3B | +33% |
| Q4 2025 | $59.9B | +24% |
| Q3 2025 | $51.2B | +26% |
| Q2 2025 | $47.5B | +22% |
| Q1 2025 | $42.3B | +16% |
| Q4 2024 | $48.4B | +21% |
META has the edge over PHI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | -20 points |
| Q2 2026 | 31% | -12 points |
| Q1 2026 | 41% | -0.9 points |
| Q4 2025 | 41% | -7 points |
| Q3 2025 | 40% | -2.7 points |
| Q2 2025 | 43% | +5 points |
| Q1 2025 | 41% | +3.6 points |
| Q4 2024 | 48% | +7.4 points |
META's operating margin was 20% last quarter, down 20 points from the same quarter a year ago, near the bottom of its range since 2019.
PHI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $873.8M | +2.2% |
| Q1 2026 | $889.9M | +2.2% |
| Q4 2025 | $864.8M | -1.7% |
| Q3 2025 | $845.7M | +0.7% |
| Q2 2025 | $855M | +1.8% |
| Q1 2025 | $870.4M | +1.9% |
| Q4 2024 | $880.1M | +2.4% |
| Q3 2024 | $840.2M | +2% |
PHI's revenue grew through 2022 and has held roughly level since: $874M last quarter, up 2.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 52% | +25 points |
| Q1 2026 | 50% | +22 points |
| Q4 2025 | 14% | -4.1 points |
| Q3 2025 | 52% | +46 points |
| Q2 2025 | 27% | +3.8 points |
| Q1 2025 | 28% | -0.6 points |
| Q4 2024 | 18% | -25 points |
| Q3 2024 | 5.8% | -46 points |
PHI has the edge over META on profitability, with a higher operating margin.
META Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -110% |
| Q2 2026 | $1.7B | -81% |
| Q1 2026 | $13.2B | +19% |
| Q4 2025 | $14.8B | +9.3% |
| Q3 2025 | $11.2B | -32% |
| Q2 2025 | $9B | -19% |
| Q1 2025 | $11.1B | -14% |
| Q4 2024 | $13.6B | +16% |
META usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $28.6B over the past year.
PHI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $183.9M | +176% |
| Q1 2026 | $115.6M | -13% |
| Q4 2025 | $134.2M | +$228.6M |
| Q3 2025 | $173.9M | +88% |
| Q2 2025 | $66.5M | -51% |
| Q1 2025 | $132.3M | +68% |
| Q4 2024 | -$94.4M | -172% |
| Q3 2024 | $92.4M | -54% |
PHI has the edge over META on cash flow, with more consistent year-over-year improvement.
META Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +7M shares |
| 1 year | 0% | +1M shares |
| 3 years | -2.6% | -68M shares |
| 5 years | -10% | -286M shares |
| Available history | -11% | -303M shares |
META has 2.6B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $3.3B |
| Q2 2025 | $10.2B |
| Q1 2025 | $12.8B |
| Q4 2024 | — |
META hasn't bought back shares in the past year.
PHI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -428K shares |
| 1 year | -0.2% | -442K shares |
| 3 years | 0% | -5K shares |
| 5 years | -0.2% | -520K shares |
| Available history | -0.5% | -1M shares |
PHI has the edge over META on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
PHI hasn't bought back shares in the past year.
META Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.6x | Very low |
| Q1 2026 | 0.3x | Very low |
| Q4 2025 | 0.2x | Very low |
| Q3 2025 | 0.2x | Very low |
| Q2 2025 | 0.2x | Very low |
| Q1 2025 | 0.0x | Very low |
| Q4 2024 | -0.2x | Net Cash |
META has the edge over PHI on leverage, with a lower net debt burden relative to earnings.
PHI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 3.2x | Elevated |
| Q1 2026 | 3.2x | Elevated |
| Q4 2025 | 3.7x | Elevated |
| Q3 2025 | 3.1x | Elevated |
| Q2 2025 | 3.0x | Moderate |
| Q1 2025 | 3.0x | Moderate |
| Q4 2024 | 3.1x | Elevated |
| Q3 2024 | 3.4x | Elevated |
PHI's net debt is about 3.2 years of its operating earnings (EBITDA), up from 3.0 years a year ago.
META Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.2 | Neutral |
| Stochastic | 33.7 | Neutral |
META's weekly RSI is 48 (neutral) and its Stochastic is 34 (neutral).
PHI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.4 | Neutral |
| Stochastic | 24.6 | Neutral |
PHI's weekly RSI is 36 (neutral) and its Stochastic is 25 (neutral).
META PE vs Communication Services Sector
| Metric | META | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 16x | 29% above |
| PE % | 18 | 26 | 8 pts below |
META is trading at 21x earnings, a 29% premium to the Communication Services sector's median of 16x.
PHI PE vs Communication Services Sector
| Metric | PHI | Sector median | Relative |
|---|---|---|---|
| PE | 7.8x | 16x | 53% below |
| PE % | 5 | 26 | 21 pts below |
PHI has the edge over META on valuation relative to its sector.
META Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $674.9 | 7.6% below |
| 20 week MA | $634.5 | 1.7% below |
| 50 week MA | $630.8 | 1.1% below |
| 100 week MA | $647.8 | 3.7% below |
| 200 week MA | $517.5 | 21% above |
META has the edge over PHI on trend strength, trading above more of its moving averages.
PHI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $18.0 | 10% below |
| 20 week MA | $18.6 | 13% below |
| 50 week MA | $20.0 | 20% below |
| 100 week MA | $21.0 | 23% below |
| 200 week MA | $22.4 | 28% below |
PHI is in a downtrend: it's below all five of its weekly moving averages, and 28% below its 200-week average.
META Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $208.1 | $267.4 | +28% |
| 2021 | $267.4 | $335.2 | +25% |
| 2022 | $335.2 | $118.0 | -65% |
| 2023 | $118.0 | $354.0 | +200% |
| 2024 | $354.0 | $599.8 | +69% |
| 2025 | $599.8 | $663.3 | +11% |
| 2026 YTD | $663.3 | $623.6 | -6% |
META has the edge over PHI on returns for 2026, with the stronger performance.
PHI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $19.8 | $28.0 | +41% |
| 2021 | $28.0 | $37.0 | +32% |
| 2022 | $37.0 | $22.7 | -39% |
| 2023 | $22.7 | $23.4 | +3.4% |
| 2024 | $23.4 | $22.1 | -5.8% |
| 2025 | $22.1 | $21.7 | -1.9% |
| 2026 YTD | $21.7 | $16.1 | -26% |
PHI has finished lower in three of the last six years. It's down 26% so far in 2026.